Michael Mark

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ele Ferrannini, Michael Mark, Eric Mayoux · Diabetes Care · 2016 · 948 citations

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 583 citations

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

Issei Tomita, Shinji Kume, Sho Sugahara et al. · Cell Metabolism · 2020 · 337 citations · Full text

Renal Function, Signal Transduction, Medicine +7

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Matthias Eckhardt, Elke Langkopf, Michael Mark et al. · Journal of Medicinal Chemistry · 2007 · 281 citations · Full text

Pharmaceutical Science, Xanthine Scaffold, Pharmacotherapy +17

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

Matthias Kern, Nora Klöting, Michael Mark et al. · Metabolism · 2015 · 114 citations

Metabolic Syndrome, Insulin Sensitivity, Diabetes Management +11